Market Cap 2.62B
Revenue (ttm) 0.00
Net Income (ttm) -175.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1,080.19
Profit Margin 0.00%
Debt to Equity Ratio 0.10
Volume 365,600
Avg Vol 1,820,378
Day's Range N/A - N/A
Shares Out 53.71M
Stochastic %K 37%
Beta -3.15
Analysts Strong Sell
Price Target $113.83

Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was i...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 213 8444
Fax: 650 213 8383
Website: soleno.life
Address:
100 Marine Parkway, Suite 400, Redwood City, United States
RandomInvestor777
RandomInvestor777 Dec. 24 at 1:38 AM
$SLNO Massively undervalued. mostly due to a shitty short report should be $100+ by next year. buyout within that range as well before Q3 2026. Already had two buyout rumors.
1 · Reply
Quantumup
Quantumup Dec. 23 at 12:17 PM
Oppenheimer🏁 $AARD Outperform-$35 and said: We initiate coverage with an Outperform rating and a $35 PT as AARD builds a differentiated rare and common obesity franchise-and ahead of next year's key readout. $SLNO $RYTM Oppenheimer added: Lead program is a global Phase 3 trial for Prader-Willi syndrome, a $1B+ US TAM for which favorable safety alone could make ARD-101 competitive to the sole currently approved option. Topline data due 3Q26. AARD is also pursuing several avenues to advance the treatment condition for general obesity, for which injectable GLP-1 drugs—despite their impressive sales growth—are far from perfect and have created opportunities for innovative oral therapeutics that could be used in complement with them or as independent alternatives. Cash runway sufficient to reach key catalysts that we expect to drive share outperformance from current <$200M EV.
0 · Reply
Biocontrol
Biocontrol Dec. 20 at 12:12 AM
$SLNO calling 105M here for q4.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:44 PM
$SLNO: Current market context shows the stock closing at $48.38, with an RSI of 43.62 indicating it is nearing oversold conditions. The 30-day moving average (MA30) is at $48.7, slightly above the current price, while the 50-day moving average (MA50) is significantly higher at $55.31. This suggests a bearish short-term trend but potential for a rebound as it approaches the lower end of the 60-day range ($41.8). Directional bias leans bullish due to the proximity to the 60D low and the RSI indicating potential upward momentum. Suggested trade plan: - Entry: $48.50 - Stop Loss: $45.50 (approximately 6% below entry) - Take Profit Targets: 1. $52.00 (Target 1, 7.7% ROI) 2. $55.00 (Target 2, 13.0% ROI) 3. $56.70 (Target 3, 17.1% ROI) This plan aims for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
CH_Expat
CH_Expat Dec. 19 at 3:26 PM
$SLNO In with 530 for 47.80 USD. Send it.
3 · Reply
CH_Expat
CH_Expat Dec. 18 at 7:55 PM
$SNDX $NKTR $SLNO are some non-shit bios that look undervalued right now. But for some reason I cannot pull the trigger for starters.
1 · Reply
Quantumup
Quantumup Dec. 17 at 4:24 PM
Guggenheim⬆️ $RYTM's PT to $140/reit'd at Buy $SLNO $AARD Canaccord Genuity 12/12⬆️PT to $141 from $114, plus added $2.1 B peak sale@ 50% PoS in PWS to its model; reit'd Buy Citizens 12/12⬆️PT to $167 from $141—reit'd Mkt OP/now includes PWS@ 50% POS/peak🇺🇸sales=$700M in '32 Here's what the Analysts had to say:
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 17 at 3:04 PM
$SLNO Looking to buy a dip...
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 4:29 AM
$SLNO: Current market context shows a close at $49.5, with an RSI of 49.17 indicating a neutral momentum. The MA30 at $49.13 supports a slight bullish bias, while the MA50 at $55.85 suggests potential resistance above. Given the 60D high of $72.88 and low of $41.8, there is a significant range to exploit. Actionable Trade Plan: - Suggested Entry: $49.5 - Stop Loss: $47.5 (1.5 ATR below entry) - Take Profit Targets: 1. Target 1: $53.0 (10% ROI) 2. Target 2: $57.5 (15% ROI) 3. Target 3: $58.0 (17% ROI) With the current RSI and MAs indicating a potential upward move, this trade plan leverages the volatility indicated by the ATR. The targets are set to capture gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
QuantInsider
QuantInsider Dec. 16 at 9:12 PM
$SLNO taking a hit, down about 7% over the last five days with that securities law investigation hanging over it Not looking great Saw a cluster of about 1,532 Mar 2026 $80 calls at 10:16 AM on InsiderFinance They're way OTM and it's just average volume Feels more like speculative action than a solid reversal signal No strong directional edge here with the current legal overhang Just keeping an eye on it for now
0 · Reply
Latest News on SLNO
Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm

Nov 12, 2025, 10:56 AM EST - 6 weeks ago

Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm


Soleno: Blockbuster Launch In Progress

Oct 11, 2025, 8:45 AM EDT - 2 months ago

Soleno: Blockbuster Launch In Progress


Soleno Therapeutics Announces VYKAT(TM) XR Launch

Apr 14, 2025, 7:00 AM EDT - 9 months ago

Soleno Therapeutics Announces VYKAT(TM) XR Launch


RandomInvestor777
RandomInvestor777 Dec. 24 at 1:38 AM
$SLNO Massively undervalued. mostly due to a shitty short report should be $100+ by next year. buyout within that range as well before Q3 2026. Already had two buyout rumors.
1 · Reply
Quantumup
Quantumup Dec. 23 at 12:17 PM
Oppenheimer🏁 $AARD Outperform-$35 and said: We initiate coverage with an Outperform rating and a $35 PT as AARD builds a differentiated rare and common obesity franchise-and ahead of next year's key readout. $SLNO $RYTM Oppenheimer added: Lead program is a global Phase 3 trial for Prader-Willi syndrome, a $1B+ US TAM for which favorable safety alone could make ARD-101 competitive to the sole currently approved option. Topline data due 3Q26. AARD is also pursuing several avenues to advance the treatment condition for general obesity, for which injectable GLP-1 drugs—despite their impressive sales growth—are far from perfect and have created opportunities for innovative oral therapeutics that could be used in complement with them or as independent alternatives. Cash runway sufficient to reach key catalysts that we expect to drive share outperformance from current <$200M EV.
0 · Reply
Biocontrol
Biocontrol Dec. 20 at 12:12 AM
$SLNO calling 105M here for q4.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:44 PM
$SLNO: Current market context shows the stock closing at $48.38, with an RSI of 43.62 indicating it is nearing oversold conditions. The 30-day moving average (MA30) is at $48.7, slightly above the current price, while the 50-day moving average (MA50) is significantly higher at $55.31. This suggests a bearish short-term trend but potential for a rebound as it approaches the lower end of the 60-day range ($41.8). Directional bias leans bullish due to the proximity to the 60D low and the RSI indicating potential upward momentum. Suggested trade plan: - Entry: $48.50 - Stop Loss: $45.50 (approximately 6% below entry) - Take Profit Targets: 1. $52.00 (Target 1, 7.7% ROI) 2. $55.00 (Target 2, 13.0% ROI) 3. $56.70 (Target 3, 17.1% ROI) This plan aims for a minimum of 17% ROI on the third target while managing risk effectively. https://privateprofiteers.com
0 · Reply
CH_Expat
CH_Expat Dec. 19 at 3:26 PM
$SLNO In with 530 for 47.80 USD. Send it.
3 · Reply
CH_Expat
CH_Expat Dec. 18 at 7:55 PM
$SNDX $NKTR $SLNO are some non-shit bios that look undervalued right now. But for some reason I cannot pull the trigger for starters.
1 · Reply
Quantumup
Quantumup Dec. 17 at 4:24 PM
Guggenheim⬆️ $RYTM's PT to $140/reit'd at Buy $SLNO $AARD Canaccord Genuity 12/12⬆️PT to $141 from $114, plus added $2.1 B peak sale@ 50% PoS in PWS to its model; reit'd Buy Citizens 12/12⬆️PT to $167 from $141—reit'd Mkt OP/now includes PWS@ 50% POS/peak🇺🇸sales=$700M in '32 Here's what the Analysts had to say:
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 17 at 3:04 PM
$SLNO Looking to buy a dip...
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 4:29 AM
$SLNO: Current market context shows a close at $49.5, with an RSI of 49.17 indicating a neutral momentum. The MA30 at $49.13 supports a slight bullish bias, while the MA50 at $55.85 suggests potential resistance above. Given the 60D high of $72.88 and low of $41.8, there is a significant range to exploit. Actionable Trade Plan: - Suggested Entry: $49.5 - Stop Loss: $47.5 (1.5 ATR below entry) - Take Profit Targets: 1. Target 1: $53.0 (10% ROI) 2. Target 2: $57.5 (15% ROI) 3. Target 3: $58.0 (17% ROI) With the current RSI and MAs indicating a potential upward move, this trade plan leverages the volatility indicated by the ATR. The targets are set to capture gains while managing risk effectively. https://privateprofiteers.com
0 · Reply
QuantInsider
QuantInsider Dec. 16 at 9:12 PM
$SLNO taking a hit, down about 7% over the last five days with that securities law investigation hanging over it Not looking great Saw a cluster of about 1,532 Mar 2026 $80 calls at 10:16 AM on InsiderFinance They're way OTM and it's just average volume Feels more like speculative action than a solid reversal signal No strong directional edge here with the current legal overhang Just keeping an eye on it for now
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 8:02 AM
$SLNO: Current market context shows a strong upward momentum but is nearing overbought conditions with an RSI of 68.74. The last close at $52.00 is above the 30-day moving average of $50.25, indicating bullish sentiment. However, it is below the 50-day moving average of $56.22, suggesting potential resistance ahead. The 60-day high of $72.88 provides a critical reference point for profit-taking. Actionable Trade Alert: - Suggested Entry: $52.50 - Stop Loss: $49.50 (3.81% below entry) - Take Profit Targets: 1. $58.00 (10.57% ROI) 2. $65.00 (23.81% ROI) 3. $70.00 (33.33% ROI) Target 3 offers a potential ROI of over 17%. The directional bias remains bullish, but traders should monitor the RSI closely for signs of reversal. https://privateprofiteers.com
0 · Reply
Windy007
Windy007 Dec. 12 at 3:49 AM
$SLNO Life Sci Advisors
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:56 AM
$SLNO: The last close at $49.94 indicates a potential upward movement, but the RSI at 66.01 suggests it's approaching overbought territory. The price is currently below the 30-day moving average (MA30 at $50.84) and significantly below the 50-day moving average (MA50 at $56.35), indicating a bearish trend in the short to medium term. The 60-day high of $72.88 presents a resistance level, while the low of $41.80 offers support. Actionable Trade Plan: - Suggested Entry: $50.50 (above MA30) - Stop Loss: $47.50 (below recent support) - Take Profit Targets: 1. $55.00 (10% ROI) 2. $60.00 (18% ROI) 3. $65.00 (30% ROI) With a favorable risk-reward setup, this trade allows for a potential 30% ROI at target 3 while maintaining a manageable stop loss. Monitor RSI and price action closely for any reversal signs. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 11:13 PM
$SLNO Current Stock Price: $49.45 Contracts to trade: $50 SLNO Dec 19 2025 Call Entry: $1.10 Exit: $1.86 ROI: 69% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CH_Expat
CH_Expat Dec. 11 at 7:17 PM
$SLNO Need to think about it. If it stays flat or red for a few days, I might jump in. All fears aside, they will do 350-400m revenue in 2026 and have 550m in the bank. Valuewise much better play than most expensive bios right now.
1 · Reply
Quantumup
Quantumup Dec. 11 at 6:30 PM
BofA⬆️ $RYTM's PT to $140 from $127, reiterated at a Buy rating and said, 'Encouraging Early BMI and Hyperphagia Reduction Signal—Model Changes' $SLNO $AARD Morgan Stanley⬆️PT to $150 from $129, reit'd at Buy/said, Preliminary Ph2 setmelanotide data in PWS indicate promising and consistent signs of activity (BMI and hyperphagia) despite a challenging population supporting advancement into Ph3. We view early data as encouraging, indicating potential to expansion into another blockbuster opportunity. Here's what else BofA had to say: https://x.com/Quantumup1/status/1999184429684822485?s=20
0 · Reply
Quantumup
Quantumup Dec. 11 at 5:31 PM
Raymond James reiterated $AARD Strong Buy/$47 $RYTM $SLNO Raymond James said—Remain Strong Buy rated on AARD shares following Rhythm's (RYTM, not covered) presentation of preliminary Phase 2 data for setmelanotide in PWS. Recall, this drug's mechanism differs from ARD-101 and it appears the drug's clinical utility differs as well. As we highlight herein, setmelanotide appears to impact BMI more that hyperphagia, and given the complexity of this disease, we think combination therapy is likely where standard of care is headed. Given this, we think ARD-101's value proposition as potentially best-in-class in controlling hyperphagia remains intact.
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 11 at 2:39 PM
$SLNO On the list of top 10 M&A candidates in bio. Shorts roasting....like in TMDX. Bio is back and the cash flows are positive across the board. Shorts had their time.
0 · Reply
CrispDry
CrispDry Dec. 11 at 2:34 PM
$SLNO I think we are safe
0 · Reply
DLAT94
DLAT94 Dec. 11 at 1:09 PM
$SLNO & with that they are proceeding to a ph3 study? Looks like casino roulette to me.
1 · Reply
CrispDry
CrispDry Dec. 11 at 12:05 AM
$SLNO on watch for $RYTM data.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:59 AM
$SLNO: Current market context shows a close at $50.01 with an RSI of 53.85, indicating neutral momentum. The 30-day moving average (MA30) at $52.13 suggests potential upward movement, while the 50-day moving average (MA50) at $56.9 indicates resistance. The 60-day high of $72.88 provides a target for bullish sentiment, while the 60-day low of $41.8 offers a safety net for downside risk. Directional bias is slightly bullish due to the RSI being above 50 and the price trading above MA30. Suggested entry is at $50.50, with a stop loss at $48.00 to limit risk. Take Profit Targets: 1. TP1: $54.00 (7.4% ROI) 2. TP2: $58.00 (14.9% ROI) 3. TP3: $59.00 (17.8% ROI) This plan allows for a solid risk-reward ratio, capitalizing on potential upward momentum while managing downside risk effectively. https://privateprofiteers.com
0 · Reply